Centessa Pharmaceuticals, LLC

Centessa Pharmaceuticals Plc (CNTA) appointed Stephen Kanes, a neuropsychiatrist with over 30 years in neuroscience and drug development, as Chief Medical Officer. Kanes was previously CEO of EmbarkNeuro and held roles at AstraZeneca and the University of Pennsylvania.

Centessa appoints new CMO; EyePoint expands board; Air Industries wins $5.9M Air Force contract; I-Mab Chairman to buy $2M ADS; FDA accepts Agios' sNDA; Butterfly Network projects 35% Q4 growth; uniQure prices $75M offering; Synopsys' Ansys acquisition plan accepted; Viking begins obesity drug trial; Jasper reports positive study data; Boston Scientific to acquire Bolt Medical; AMD invests $20M in Absci; Shutterstock appoints new CMO; EVgo secures $75M for expansion; Tiziana's foralumab shows promise; EDAP initiates pancreatic cancer trial; SDIC Power holds EGM; Global Petroleum delivers Lidar data; N2OFF granted Nasdaq extension; NW Natural completes SiEnergy acquisition; Cadogan Energy reports shareholder change; UK auctions £4.25B Gilt; KBN initiates pre-stabilization; Lufthansa launches subordinated debt; Morgan Stanley to stabilize Türkiye İş Bankası securities; Hon Hai sells assets for NTD 358.8M; OTE completes share buyback; Evonik launches EUR 500M bond.

Centessa Pharmaceuticals appointed Stephen Kanes MD PhD as Chief Medical Officer, leveraging his 30+ years in neuroscience and drug development. The company, with a strong financial position, focuses on OX2R agonists for sleep-wake and psychiatric disorders, advancing ORX750 in Phase 2 trials. Its LockBody technology aims to improve cancer treatment efficacy and safety.

Centessa Pharmaceuticals appointed Stephen Kanes MD PhD as Chief Medical Officer. Kanes, with over 30 years in neuroscience and psychiatry, will advance Centessa's OX2R agonists for treating sleep-wake and psychiatric disorders. ORX750, their lead agonist, is in Phase 2 trials for narcolepsy and idiopathic hypersomnia.

Centessa Pharmaceuticals' stock fell 3.2% to $15.82, with trading volume down 87%. Analysts rate it 'Buy' with a $25.83 target. The company reported a smaller loss than expected. Insiders sold shares, reducing their holdings. Institutional investors increased stakes, owning 82.01% of the company.

Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.

Amgen's MariTide linked to bone density loss, Lexeo Therapeutics gains FDA agreement for Friedreich ataxia gene therapy, AstraZeneca to invest $3.5B in U.S. facilities, Roche pays Flare Therapeutics $70M for oncology drug development, Novartis collaborates with Schrödinger for drug discovery, Centessa halts hemophilia B treatment development.

Centessa Pharmaceuticals initiates Phase 2 trial of ORX750, an OX2R agonist for narcolepsy and idiopathic hypersomnia, triggering a $3.5 million milestone payment to Nxera.

AnaptysBio's Q3 2024 10-Q report shows collaboration revenue up to $30.0M, with a net loss of $(32.9)M. The company advances its pipeline, including rosnilimab in Phase 2b for RA and UC, and ANB032 in Phase 2b for AD. Challenges include product development risks and regulatory approval hurdles.

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.